Decreased sEng plasma levels in hypertensive patients with endothelial dysfunction under chronic treatment with Perindopril.

Abstract

Purpose: Endoglin is a transmembrane glycoprotein which plays an important role in maintaining cardiovascular homeostasis. One of its forms, soluble endoglin (sEng), a molecule with antiangiogenic properties, has been found overexpressed in patients suffering from hypercholesterolemia, diabetes mellitus and hypertension, and is proposed as a marker of endothelial damage. Accordingly, we aimed to quantify the efficacy of various antihypertensive regimens on sEng levels, in hypertensive patients with endothelial dysfunction. Patients and methods: 323 patients were enrolled, and there were 99 patients with normal blood pressure values, 106 hypertensive patients under chronic treatment with different types of antihypertensive molecules (beta blockers, calcium channel blockers, and diuretics) in monotherapy, and 118 hypertensive patients under chronic treatment with perindopril. sEng plasma levels were quantified and were correlated with classical methods of assessing the endothelial damage. Results: Patients under chronic treatment with perindopril had lower sEng plasma levels compared with the other group of hypertensive patients under different regimens of antihypertensive treatment (sEng: 4.73±1.39 versus 5.63±2.33, p<0.01). Conclusion: Decreased sEng plasma levels were found in patients under chronic treatment with perindopril, when compared with other antihypertensive regimens of treatment (beta blockers, calcium channel blockers, and/or diuretics).

• Authors: Valentina Buda, Minodora Andor, Dana Emilia Baibata, Ramona Cozlac, Gabriela Radu, Dorina Coricovac, Corina Danciu, Ionut Ledeti, Adelina Cheveresan, Cristian Nica, Paul Tuduce, Mirela Cleopatra Tomescu
• Journal: Drug design, development and therapy (Drug Des Devel Ther) Vol. 13 Pg. 1915-1925 ( 2019) ISSN: 1177-8881 [Electronic] New Zealand
• PMID: 31239642 (Publication Type: Journal Article)

Chemical References

• Antihypertensive Agents
• Endoglin
• Perindopril

Topics

• Antihypertensive Agents (administration & dosage, pharmacology)
• Blood Pressure (drug effects)
• Cross-Sectional Studies
• Endoglin (antagonists & inhibitors, blood)
• Endothelium, Vascular (drug effects, metabolism)
• Female
• Humans
• Hypertension (drug therapy, metabolism)
• Male
• Middle Aged
• Perindopril (administration & dosage, pharmacology)
• Solubility